Cargando…

Modelling CAR-T therapy in humanized mice

Detalles Bibliográficos
Autores principales:	Wu, Yongxia, Yu, Xue-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413350/ https://www.ncbi.nlm.nih.gov/pubmed/30665855 http://dx.doi.org/10.1016/j.ebiom.2019.01.029

Ejemplares similares

Dynamic fine-tuning of CAR-T cell therapy
por: Trehin, Pierre V.M., et al.
Publicado: (2023)

CAR-T cell therapy in myeloma: hopes and hurdles
por: Harousseau, Jean Luc
Publicado: (2023)

A multi‐omics perspective of CAR T cell therapy
por: Yang, Jingwen, et al.
Publicado: (2023)

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Choi, Gyeyoung, et al.
Publicado: (2022)

Cars, CONSORT 2010, and Clinical Practice
por: Williams, Hywel C
Publicado: (2010)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Buckling up against COVID-19 after CAR T-cell therapy
por: Auletta, Jeffery J.
Publicado: (2022)

CAR-macrophage: An extensive immune enhancer to fight cancer
por: Wang, Shuhang, et al.
Publicado: (2022)

Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
por: Locke, Frederick L., et al.
Publicado: (2017)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
por: Zhang, Jie, et al.
Publicado: (2020)

TriKEs and BiKEs join CARs on the cancer immunotherapy highway
por: Tay, Szun Szun, et al.
Publicado: (2016)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

Timing and regulation of hematopoietic stem cell colonization of the human fetal bone marrow by endothelial and CAR stromal cells during pregnancy
por: Lapidot, Tsvee
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity
por: Pensato, Umberto, et al.
Publicado: (2021)

Increase of diesel car raises health risk in spite of recent development in engine technology
por: Leem, Jong Han, et al.
Publicado: (2014)

Chimeric miRNA cluster enables multiplex and titratable gene inhibition in CAR-T cells
por: Haraszti, Reka Agnes
Publicado: (2023)

A Last Call for Europe's Car Industry
por: Seidel, Philipp
Publicado: (2020)

Plug-in Hybrids Will Become Mainstream in Passenger Car Drives
por: Hannibal, Wilhelm
Publicado: (2020)

Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car
por: Wattjes, Mike P., et al.
Publicado: (2012)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Mesenchymal stromal cells and leukemia therapy in mice and man
por: Gale, Robert Peter
Publicado: (2020)

A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone
por: Cui, Yuanbin, et al.
Publicado: (2022)

A big STEP (Simultaneous Tumor and Effector Profiling) forward in the battle against chimeric antigen receptor (CAR) T-cell therapy resistance
por: Sondhi, Anya K., et al.
Publicado: (2023)

mSphere of Influence: Of Mice, Men, and Microbes—How Well Do Experimental Models Recapitulate Human Infection?
por: Armbruster, Chelsie E.
Publicado: (2021)

Reawakening GDNF's regenerative past in mice and humans
por: Samos, Andres, et al.
Publicado: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice
por: Wu, Yongxia, et al.
Publicado: (2021)

Interspecific variation of olfactory preferences in flies, mice, and humans
por: Manoel, Diogo, et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Lymphocytes, apoptosis and sepsis: making the jump from mice to humans
por: Lang, John D, et al.
Publicado: (2009)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Humans as holobionts: implications for prevention and therapy
por: van de Guchte, Maarten, et al.
Publicado: (2018)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
por: Baidoun, Firas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oc19rgf47dcmb42pg1s0avq0ok